HAIFA, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company
developing novel placenta-based cell therapy products, today announced that it will host a Key Opinion Leader (KOL) meeting on
Peripheral Artery Disease (PAD) on December 14, 2018 in New York City.
The meeting will feature presentations by KOLs John Lantis, MD, Vice Chairman of the Department of Surgery and
Chief of Vascular and Endovascular Surgery at Mount Sinai West, and Mary L. Yost, MBA, Co-Founder of The Sage Group, who will
discuss the current treatment landscape and unmet medical needs, the economic impact, and potential market opportunities for
treating patients with PAD. Both KOLs will be available at the conclusion of the event to answer questions.
Pluristem's management team will also provide a corporate overview of the company's development strategy for
PLX-PAD, which is currently in a multinational pivotal Phase III clinical study. Of note, the FDA recently approved an Expanded
Access Program (EAP) for PLX-PAD in CLI patients. It is estimated that 5-6 million people in U.S. and Europe suffer from CLI, and
this number is projected to grow, with an estimated cost of $25 billion per year in the U.S. alone.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business
development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to
attend in person, a live webcast and replay will be accessible here. If you would like to ask a question during the live Q&A, please submit your request
via email.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy products. The
Company has reported robust clinical trial data in multiple indications for its patented PLX cells and is entering late stage
trials in several indications. PLX cell products release a range of therapeutic proteins in response to inflammation, ischemia,
muscle trauma, hematological disorders, and radiation damage. The cells are grown using the Company's proprietary three-dimensional
expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong
intellectual property position; Company-owned and operated, GMP-certified manufacturing and research facilities; strategic
relationships with major research institutions; and a seasoned management team.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of
1995 and other U.S. Federal securities laws. For example, we are using forward-looking statements when we discuss the estimated
growth in the population in the U.S. and Europe suffering from CLI and projected cost of treatment of CLI in the U.S. These
forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and
are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in
the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our
technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be
unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the
laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate
with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in
legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and
pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ
materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties
affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange
Commission.
Contact:
Efrat Kaduri
Head of Investor and Public Relations
972-74-7108600
efratk@pluristem.com
Karine Kleinhaus, MD, MPH
Divisional VP, North America
1-914-512-4109
karinek@pluristem.com
